Tenofovir Alafenamide Fumarate Reduces Virological Replication in HBeAg ‐Negative Patients With Normal Alanine Aminotransferase: A 48‐Week Randomised Controlled Trial
Journal of Viral Hepatitis · 2026
DOI: 10.1111/jvh.70141 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Viral Hepatitis, 2026. Verfasst von Qiumin Luo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Disease, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Alanine Transaminase, Antiviral Agents, Hepatitis B virus. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Basic and Applied Basic Research Foundation of Guangdong Province, Guangzhou Municipal Science and Technology Program key projects.
Abstract (Originalsprache)
The optimal strategy for chronic hepatitis B virus (HBV) infected patients with negative hepatitis B e‐antigen (HBeAg) and normal alanine aminotransferase (ALT) remains uncertain. This study aimed to evaluate the safety and efficacy of tenofovir alafenamide fumarate (TAF) treatment in this patient population. This prospective, open‐label, randomised controlled trial enrolled HBeAg‐negative patients with normal ALT and randomised them 1:1 to either the treatment group (TAF) or the control group (no treatment). The primary endpoint was the reduction in hepatitis B surface antigen (HBsAg) levels from baseline to week 48. A total of 62 patients were enrolled and followed up by 48 weeks ( n = 31 per group). No serious adverse events were reported. At week 48, there was no significant difference in the change in HBsAg between the treatment and control groups [0.01 (−0.06, 0.05) vs. −0.05 (−0.12, 0.06) log 10 IU/mL, p = 0.354]. However, HBV DNA levels were significantly lower in the treatment group (0 vs. 2.86 log 10 IU/mL, p < 0.001). All patients achieved HBV DNA below 20 IU/mL after treatment. Additionally, chitinase‐3‐like protein 1 level was lower in the treatment group (23.8 vs. 44.8 ng/mL, p = 0.019). TAF was well‐tolerated in HBeAg‐negative patients with normal ALT and low‐level HBV DNA viremia. Treatment for 48 weeks led to a high rate of HBV DNA suppression and may potentially delay liver fibrosis progression. Accordingly, early antiviral treatment may benefit this patient population. Trial Registration: Clinical trial number: NCT 04231565
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Disease, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
- Guangdong Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
ORCID-Profile: Wenxiong Xu, Chan Xie, Liang Peng
Förderung
- National Natural Science Foundation of China
- Basic and Applied Basic Research Foundation of Guangdong Province
- Guangzhou Municipal Science and Technology Program key projects
- Guangzhou Municipal Science and Technology Project
- Sun Yat-Sen University Clinical Research 5010 Program
- Five-Year Plan of Third Affiliated Hospital of Sun Yat-sen University
Zitieren
APA
Luo, Q., Xu, W., Zhang, Y., Li, X., Lai, J., Li, J., Zheng, X., Deng, H., Chen, L., Zhu, X., Xie, C., & Peng, L. (2026). Tenofovir Alafenamide Fumarate Reduces Virological Replication in HBeAg ‐Negative Patients With Normal Alanine Aminotransferase: A 48‐Week Randomised Controlled Trial. Journal of Viral Hepatitis. https://doi.org/10.1111/jvh.70141
Vancouver
Luo Q, Xu W, Zhang Y, Li X, Lai J, Li J, et al. Tenofovir Alafenamide Fumarate Reduces Virological Replication in HBeAg ‐Negative Patients With Normal Alanine Aminotransferase: A 48‐Week Randomised Controlled Trial. Journal of Viral Hepatitis. 2026. doi:10.1111/jvh.70141
BibTeX
@article{Luo2026,
author = {Luo, Qiumin and Xu, Wenxiong and Zhang, Yeqiong and Li, Xiangyong and Lai, Jing and Li, Jianguo and Zheng, Xingrong and Deng, Hong and Chen, Lubiao and Zhu, Xiang and Xie, Chan and Peng, Liang},
title = {Tenofovir Alafenamide Fumarate Reduces Virological Replication in HBeAg ‐Negative Patients With Normal Alanine Aminotransferase: A 48‐Week Randomised Controlled Trial},
journal = {Journal of Viral Hepatitis},
year = {2026},
doi = {10.1111/jvh.70141}
}
EUVIMED